Cluster

The GLP-1 Effect on Spirits

TL;DR

Ozempic, Wegovy, and Mounjaro are reshaping alcohol consumption. Forecast how Big Six earnings calls, volume guidance, and retail data shift.

Every major spirits CEO now fields GLP-1 questions on earnings calls. The clinical data is real, the consumer behavior is messier, and the long-term volume impact is the most-debated number on Wall Street. These markets put a probability on the next twelve months of guidance and disclosure.

4 open markets
Flashcloses in 86d
Awards

Will any 2026 Spirited Award speech reference Ozempic, GLP-1, or weight-loss medications?

popglp1spirited_awards
Crowd
no predictions yet
Predictors
0
Issuescloses in 241d

Will any Big 6 spirits CEO name GLP-1 medications as a material headwind on a 2026 earnings call?

glp1ozempicearningsbig6
Crowd
75% YES
Predictors
1+1/24h
Issuescloses in 241d

Will US off-premise alcohol dollar sales decline year-over-year for three consecutive Circana four-week periods in 2026?

glp1off_premisecircanadata
Crowd
no predictions yet
Predictors
0
Hospitalitycloses in 241d

Will a major hospitality publication run a feature on Ozempic menus in 2026?

glp1editorialmenustrend
Crowd
no predictions yet
Predictors
0
Other clusters